Emerging strategies in tumor vaccines

Current Opinion in Oncology

Volumn 14, Issue 6, 2002, Pages 641-648

  Le Poole, I Caroline ^a   Gerberi, M A Todd ^a   Kast, W Martin ^a  

^a LOYOLA UNIVERSITY HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIIDIOTYPIC ANTIBODY; B7 ANTIGEN; CARBOHYDRATE; CARCINOEMBRYONIC ANTIGEN; DENDRITIC CELL VACCINE; DNA VACCINE; EPITOPE; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 12; INTERLEUKIN 4; INTERLEUKIN 6; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; MUCIN 1; RECOMBINANT ANTIGEN; TUMOR VACCINE; UNCLASSIFIED DRUG; CANCER VACCINE; IMMUNOLOGICAL ADJUVANT; TUMOR ANTIGEN;

ANTIGENICITY; ANTINEOPLASTIC ACTIVITY; AUTOIMMUNITY; BREAST CANCER; CANCER ADJUVANT THERAPY; CLINICAL EXAMINATION; CLINICAL TRIAL; DRUG PULSE THERAPY; DRUG SAFETY; GASTROINTESTINAL TUMOR; HELPER CELL; HUMAN; LABORATORY TEST; MELANOMA; MUTATION; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; TUMOR IMMUNOLOGY; TUMOR REGRESSION; BIOASSAY; CARBOHYDRATE METABOLISM; CHEMISTRY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; IMMUNE SYSTEM; IMMUNIZATION; IMMUNOLOGY; METHODOLOGY; NEOPLASM; PHYSIOLOGY; TREATMENT OUTCOME;

ADJUVANTS, IMMUNOLOGIC; ANTIGENS, NEOPLASM; CANCER VACCINES; CARBOHYDRATE METABOLISM; CARBOHYDRATES; DENDRITIC CELLS; ENDPOINT DETERMINATION; HUMANS; IMMUNE SYSTEM; IMMUNIZATION; NEOPLASMS; T-LYMPHOCYTES, CYTOTOXIC; TREATMENT OUTCOME;

EID: 0036854217     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001622-200211000-00009     Document Type: Review

References (91)

1. Chagnon F, Thompson-Snipes L, Elhilali M, et al.: Murine renal cell carcinoma: Evaluation of a dendritic-cell tumor vaccine. BJU Int 2001, 88:418-424.
2. Schnurr M, Galambos P, Scholz C, et al.: Tumor cell lysate-pulsed human dendritic cells induce a T-cell response against pancreatic carcinoma cells: An in vitro model for the assessment of tumor vaccines. Cancer Res 2001, 61:6445-6450.
3. Habal N, Gupta RK, Bilchik AJ, et al: CancerVax, an allogeneic tumor cell vaccine, induces specific humoral and cellular immune responses in advanced colon cancer. Ann Surg Oncol 2001, 8:389-401.
4. Touloukian CE, Leitner WW, Robbins PF, et al.: Mining the melanosome for tumor vaccine targets: P. polypeptide is a novel tumor-associated antigen. Cancer Res 2001, 61:8100-8104.
5. von Mehren M, Arlen P, Gulley J, et al.: The influence of granulocyte macrophage colony-stimulating factor and prior chemotherapy on the immunologic response to a vaccine (ALVAC- CEA B7.1) in patients with metastatic carcinoma. Clin Cancer Res 2001, 7:1181-1191.
6. Tamura M, Nishizaka S, Maeda Y, et al.: Identification of cyclophilin B-derived peptides capable of inducing histocompatibility leukocyte antigen-A2-restricted and tumor-specific cytotoxic T lymphocytes. Jpn J Cancer Res 2001, 92:762-767.
7. Saeterdal I, Gjertsen MK, Straten P, et al.: A TGF betaRII frameshift-mutation-derived CTL epitope recognized by HLA- A2-restricted CD8+ T cells. Cancer Immunol Immunother 2001, 50:469-476. Characterizes newly generated T-cell clones cytolytic towards a peptide resulting from a C-terminal frameshift mutationof the TGF betaRII gene.
8. Dagher R, Long LM, Read EJ, et al.: Pilot trial of tumor-specific peptide vaccination and continuous infusion interleukin-2 in patients with recurrent Ewing sarcoma and alveolar rhabdomyosarcoma: An inter-institute NIH study. Med Pediatr Oncol 2002, 38:158-164.
9. Yamada A, Kawano K, Koga M, et al.: Multidrug resistance-associated protein 3 is a tumor rejection antigen recognized by HLA-A2402-restricted cytotoxic T lymphocytes. Cancer Res 2001, 61:6459-6466.
10. Kershaw MH, Hsu C, Mondesire W, et al.: Immunization against endogenous retroviral tumor-associated antigens. Cancer Res 2001, 61:7920-7924.
11. Nikitina EY, Chada S, Muro-Cacho C, et al.: An effective immunization and cancer treatment with activated dendritic cells transduced with full-length wild-type p53. Gene Ther 2002, 9:345-352.
12. Snijdewint FG, Mensdorff-Pouilly S, Karuntu-Wanamarta AH, et al.: Antibody-dependent cell-mediated cytotoxicity can be induced by MUC1 peptide vaccination of breast cancer patients. Int J Cancer 2001, 93:97-106.
13. Brugger W, Schneider A, Schammann T, et al.: Dendritic cell-based vaccines in patients with hematological malignancies. Ann N Y Acad Sci 2001, 938:359-362.
14. Cipolla L, Rescigno M, Leone A, et al.: Novel Tn antigen-containing neoglycopeptides: Synthesis and evaluation as anti tumor vaccines. Bioorg Med Chem 2002, 10:1639-1646.
15. Wang RF: The role of MHC class II-restricted tumor antigens and CD4+ T cells in antitumor immunity. Trends Immunol 2001, 22:269-276.
16. Rice J, Elliott T, Buchan S, et al.: DNA fusion vaccine designed to induce cytotoxic T cell responses against defined peptide motifs: Implications for cancer vaccines. J Immunol 2001, 167:1558-1565.
17. Le Gal FA, Prevost-Blondel A, Lengagne R, et al.: Lipopeptide-based melanoma cancer vaccine induced e strong MART-27-35- cytotoxic T lymphocyte response in a preclinal study. Int J Cancer 2002, 98:221-227.
18. Steitz J, Bruck J, Gambotto A, et al.: Genetic immunization with a melanocytic self-antigen linked to foreign helper sequences breaks tolerance and induces autoimmunity and tumor immunity. Gene Ther 2002, 9:208-213.
19. Toungouz M, Libin M, Bulte F, et al.: Transient expansion of peptide-specific lymphocytes producing IFN-gamma after vaccination with dendritic cells pulsed with MAGE peptides in patients with mage-A1/A3-positive tumors. J Leukoc Biol 2001, 69:937-943.
20. Casares N, Lasarte JJ, de Cerio AL, et al.: Immunization with a tumor-associated CTL epitope plus a tumor-related or unrelated Th1 helper peptide elicits protective CTL immunity. Eur J Immunol 2001, 31:1780-1789.
21. McNeel DG, Nguyen LD, Disis ML: Identification of T helper epitopes from prostatic acid phosphatase. Cancer Ree 2001, 61:5161-5167.
22. Zarour HM, Maillere B, Brusic V, et al.: NY-ESO-1 119-143 is a promiscuous major histocompatibility complex class II T-helper epitope recognized by Th1- and Th2-type tumor- reactive CD4+ T cells. Cancer Res 2002, 62:213-218.
23. Hess AD, Thoburn C, Chen W, et al.: The N-terminal flanking region of the invariant chain peptide augments the immunogenicity of a cryptic "self" epitope from a tumor-associated antigen. Clin Immunol 2001, 101:67-76.
24. Mattner F, Fleitmann JK, Lingnau K, et al.: Vaccination with poly-L-arginine as immunostimulant for peptide vaccines: Induction of potent and long-lasting T-cell responses against cancer antigens. Cancer Res 2002, 62:1477-1480.
25. Velders MP, McElhiney S, Cassetti MC, et al.: Eradication of established tumors by vaccination with Venezuelan equine encephalitis virus replicon particles delivering human papillomavirus 16 E7 RNA. Cancer Res 2001, 61:7861-7867. What is particularly interesting about this publication is the lasting tumor protection obtained by MHC class I binding peptides in the absence of CD4+ cells.
26. Smith SG, Patel PM, Porte J, et al.: Human dendritic cells genetically engineered to express a melanoma polyepitope DNA vaccine induce multiple cytotoxic T-cell responses. Clin Cancer Res 2001, 7:4253-4261.
27. van der Burg SH, Kwappenberg KM, O'Neill T, et al.: Pre-clinical safety and efficacy of TA-CIN, a recombinant HPV16 L2E6E7 fusion protein vaccine, in homologous and heterologous prime-boost regimens. Vaccine 2001, 19:3652-3660.
28. Dillman RO, Beutel LD, De Leon C, et al.: Short-term tumor cell lines from breast cancer for use as autologous tumor cell vaccines in the treatment of breast cancer. Cancer Biother Radiopharm 2001, 16:205-211.
29. Bystryn JC, Zeleniuch-Jacquotte A, Oratz R, et al.: Double-blind trial of a polyvalent, shed-antigen, melanoma vaccine. Clin Cancer Res 2001, 7:1882-1887. Amazing improvements were reported following treatment of melanoma patients with vaccines prepared from antigens shed by tumor cells.
30. Fong L, Hou Y, Rivas A, et al.: Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy. Proc Natl Acad Sci U S A 2001, 98:8809-8814
31. Schnurr M, Scholz C, Rothenfusser S, et al.: Apoptotic pancreatic tumor cells are superior to cell lysates in promoting cross-priming of cytotoxic T cells and activate NK and gamma delta T Cells. Cancer Res 2002, 62:2347-2352. Clear comparison of the efficacy of antigen sources used for pulsing dendritic cells.
32. Castiglioni P, Martin-Fontecha A, Milan G, et al.: Apoptosis-dependent subversion of the T-lymphocyte epitope hierarchy in lymphoma cells. Cancer Res 2002, 62:1116-1122.
33. Lambert LA, Gibson GR, Maloney M, et al.: Equipotent generation of protective antitumor immunity by various methods of dendritic cell loading with whole cell tumor antigens. J Immunother 2001, 24:232-236.
34. Felzmann T, Buchberger M, Lehner M, et al.: Functional maturation of dendritic cells by exposure to CD40L transgenic tumor cells, fibroblasts or keratinocytes. Cancer Lett 2001, 168:145-154.
35. Fujita N, Kagamu H, Yoshizawa H, et al.: CD40 ligand promotes priming of fully potent antitumor CD4(+) T cells in draining lymph nodes in the presence of apoptotic tumor cells. J Immunol 2001, 167:5678-5688.
36. Grosenbach DW, Barrientos JC, Schlom J, et al.: Synergy of vaccine strategies to amplify antigen-specific immune responses and antitumor effects. Cancer Res 2001, 61:4497-4505. One of the strongest reports yet in support of antitumor efficacy of costimulatory molecule enhancement.
37. Tao G, Hu J, Zou H, et al.: Therapeutic antitumor response to cervical cancer in mice immunized with U14 vaccines transfected with costimulatory B7 gene. Chin Med J 2001, 114:623-627.
38. Kinoshita Y, Kono T, Yasumoto R, et al.: Antitumor effect on murine renal cell carcinoma by autologous tumor vaccines genetically modified with granulocyte-macrophage colony- stimulating factor and interleukin-6 cells. J Immunother 2001, 24:205-211.
39. Dunussi-Joannopoulos K, Leonard JP: Interleukin-12 gene therapy vaccines: Directing the immune system against minimal residual leukemia. Leuk Lymphoma 2001, 41:483-492.
40. Lee P, Wang F, Kuniyoshi J, et al: Effects of interleukin-12 on the immune response to a multipeptide vaccine for resected metastatic melanoma. J Clin Oncol 2001, 19:3836-3847.
41. Okeda H, Villa L, Attanucci J, et al.: Cytokine gene therapy of gliomas: Effective induction of therapeutic immunity to intracranial tumors by peripheral immunization with interleukin-4 transduced glioma cells. Gene Ther 2001, 8:1157-1166.
42. Ju DW, Tao Q, Lou G, et al: Interleukin 18 transfection enhances antitumor immunity induced by dendritic cell-tumor cell conjugates. Cancer Res 2001, 61:3735-3740.
43. Winter H, Hu HM, McClain K, et al.: Immunotherapy of melanoma: A dichotomy in the requirement for IFN-gamma in vaccine-induced antitumor immunity versus adoptive immunotherapy. J Immunol 2001, 166:7370-7380. The contribution of IFN-γ to antitumor responses definitively assigned to the induction phase of the immune response.
44. Paradis TJ, Floyd E, Burkwit J, et al.: The antitumor activity of anti-CTLA-4 is mediated through its induction of IFN gamma. Cancer Immunol Immunother 2001, 50:125-133.
45. Le Poole IC, Riker A.I., Quevedo ME, et al: Interferon-gamma reduces melanosomal antigen expression and recognition of melanoma cells by cytotoxic T cells. Am J Pathol 2002, 160:521-528.
46. Fujii S, Shimizu K, Shimizu T, et al.: Interleukin-10 promotes the maintenance of antitumor CD8(+) T-cell effector function in situ. Blood 2001, 98:2143-2151.
47. Cayeux S, Qin Z, Dorken B, et al.: Decreased generation of antitumor immunity after intrasplenic immunization. Eur J Immunol 2001, 31:1392-1399. This publication furthers our understanding of the complexity of antitumor responses by presenting evidence for decreased immunogenicity of DC based vaccines delivered directly into lymphoid organs.
48. Okada N, Tsujino M, Hagiwara Y, et al.: Administration route-dependent vaccine efficiency of murine dendritic cells pulsed with antigens. Br J Cancer 2001, 84:1564-1570.
49. Iwadate Y, Yamaura A, Sato Y, et al.: Induction of immunity in peripheral tissues combined with intracerebral transplantation of interleukin-2-producing cells eliminates established brain tumors. Cancer Res 2001, 61:8769-8774.
50. Kumamoto T, Huang EK, Paek HJ, et al: Induction of tumor-specific protective immunity by in situ Langerhans cell vaccine. Nat Biotechnol 2002, 20:64-69. Away from mainstream tumor vaccinology, the authors propose a method that makes use of the special qualities of Langerhans cells to immunize tumor patients.
51. Takigawa M, Tokura Y, Hashizume H, et al.: Percutaneous peptide immunization via corneum barrier-disrupted murine skin for experimental tumor immunoprophylaxis. Ann N Y Acad Sci 2001, 941:139-146.
52. Correale P, Cusi MG, Sabatino M, et al.: Tumor-associated antigen (TAA)-specific cytotoxic T cell (CTL) response in vitro and in a mouse model, induced by TAA-plasmids delivered by influenza virosomes. Eur J Cancer 2001, 37:2097-2103.
53. Okada N, Saito T, Masunaga Y, et al.: Efficient antigen gene transduction using Arg-Gly-Asp fiber-mutant adenovirus vectors can potentiate antitumor vaccine efficacy and maturation of murine dendritic cells. Cancer Res 2001, 61:7913-7919.
54. Niethammer AG, Primus FJ, Xiang R, et al.: An oral DNA vaccine against human carcinoembryonic antigen (CEA) prevents growth and dissemination of Lewis lung carcinoma in CEA transgenic mice. Vaccine 2001, 20:421-429. This publication supports the efficacy of oral vaccine delivery (by attenuated Salmonella).
55. Gunn GR, Zubeir A, Peters C, et al.: Two Listeria monocytogenes vaccine vectors that express different molecular forms of human papilloma virus-16 (HPV-16) E7 induce qualitatively different T cell immunity that correlates with their ability to induce regression of established tumors immortalized by HPV-16. J Immunol 2001, 167:6471-6479.
56. Hung CF, He L, Juang J, et al.: Improving DNA vaccine potency by linking Marek's disease virus type 1 VP22 to an antigen. J Virol 2002, 76:2676-2682.
57. Shibagaki N, Udey MC: Dendritic cells transduced with protein antigens induce cytotoxic lymphocytes and elicit antitumor immunity. J Immunol 2002, 168:2393-2401.
58. Tanaka Y, Koido S, Chen D, et al.: Vaccination with allogeneic dendritic cells fused to carcinoma cells induces antitumor immunity in MUC1 transgenic mice. Clin Immunol 2001, 101:192-200.
59. Orentas RJ, Schauer D, Bin Q, et al.: Electrofusion of a weakly immunogenic neuroblastoma with dendritic cells produces a tumor vaccine. Cell Immunol 2001, 213:4-13.
60. Kuromatsu I, Matsuo K, Takamura S, et al.: Induction of effective antitumor immune responses in a mouse bladder tumor model by using DNA of an alpha antigen from mycobacteria. Cancer Gene Ther 2001, 8:483-490.
61. Wei WZ, Ratner S, Shibuya T, et al.: Foreign antigenic peptides delivered to the tumor as targets of cytotoxic T ceils. J Immunol Methods 2001, 258:141-150.
62. Okada T, Shah M, Higginbotham JN, et al.: AV.TK-mediated killing of subcutaneous tumors in situ results in effective immunization against established secondary intracranial tumor deposits. Gene Ther 2001, 8:1315-1322.
63. Poloso N, Nagarajan S, Bumgarner GW, et al.: Designer cancer vaccines made easy: Protein transfer of immunostimulatory molecules for use in therapeutic tumor vaccines. Front Biosci 2001, 6:D760-D775. This publication explains the novel approach of protein-mediated introduction of molecules to the surface of tumor cells.
64. Chen ZC, Tanemura M, Galili U: Synthesis of alpha-gal epitopes (Galalpha1-3Galbeta1-4GlcNAc-R) on human tumor cells by recombinant alpha1,3galactosyltransferase produced in Pichia pastoris. Glycobiology 2001, 11:577-586.
65. Galili U, Chen ZC, Manches O, et al.: Preparation of autologous leukemia and lymphoma vaccines expressing alpha-gal epitopes. J Hematother Stem Cell Res 2001, 10:501-511.
66. Wikstrand CJ, Cole VR, Crotty LE, et al.: Generation of anti-idiotypic reagents in the EGFRvIII tumor-associated antigen system. Cancer Immunol Immunother 2002, 50:639-652.
67. Alfonso M, Diaz A, Hernandez AM, et al.: An antiidiotype vaccine elicits a specific response to N-glycolyl sialic acid residues of glycoconjugates in melanoma patients. J Immunol 2002, 168:2523-2529.
68. Singh G, Parker S, Hobart P: The development of a bicistronic plasmid DNA vaccine for B-cell lymphoma. Vaccine 2002, 20:1400-1411. Lucid explanation of a vector that can serve B cell lymphoma patients with a personalized and specific antitumor vaccine.
69. Reddy SA, Okada C, Wong C, et al: T cell antigen receptor vaccines for active therapy of T cell malignancies. Ann N Y Acad Sci 2001, 941:97-105
70. Raum T, Gruber R, Riethmuller G, et al.: Anti-self antibodies selected from a human IgD heavy chain repertoire: A novel approach to generate therapeutic human antibodies against tumor- associated differentiation antigens. Cancer Immunol Immunother 2001, 50:141-150.
71. Wang Q, Yu H, Zhang L, et al.: Vaccination with IL-18 gene-modified, superantigen-coated tumor cells elicits potent antitumor immune response. J Cancer Res Clin Oncol 2001, 127:718-726.
72. Masse D, Voisine C, Henry F, et al.: Increased vaccination efficiency with apoptotic cells by silica- induced, dendritic-like cells. Cancer Res 2002, 62:1050-1056.
73. Kisseleva E, Becker M, Lemm M, et al.: Early macrophage and cytokine response during the growth of immunogenic and non-immunogenic murine tumors. Anticancer Res 2001, 21:3477-3484.
74. Spitler LE: Adjuvant therapy of melanoma. Oncology (Huntingt) 2002, 16:40-48.
75. Wu TY, Fleischmann WR, Jr.: Murine B16 melanoma vaccination-induced tumor immunity: Identification of specific immune cells and functions involved. J Interferon Cytokine Res 2001, 21:1117-1127.
76. Gough MJ, Melcher AA, Ahmed A, et al.: Macrophages orchestrate the immune response to tumor cell death. Cancer Res 2001, 61:7240-7247. In marked contrast to the undercurrent disrespect for the cell type, this publication explains the important role of macrophages as 'gatekeepers' of the immune response to tumors.
77. Banchereau J, Palucka AK, Dhodapkar M, et al.: Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine. Cancer Res 2001, 61:6451-6458.
78. Slingluff CL, Jr., Yamshchikov G, Neese P, et al.: Phase I trial of a melanoma vaccine with gp100(280-288) peptide and tetanus helper peptide in adjuvant: Immunologic and clinical outcomes. Clin Cancer Res 2001, 7:3012-3024.
79. Sosman JA, Unger JM, Liu PY, et al.: Adjuvant immunotherapy of resected, intermediate-thickness, node- negative melanoma with an allogeneic tumor vaccine: Impact of HLA class I antigen expression on outcome 1. J Clin Oncol 2002, 20:2067-2075.
80. Kim JJ, Yang JS, Nottingham LK, et al.: Induction of immune responses and safety profiles in rhesus macaques immunized with a DNA vaccine expressing human prostate specific antigen. Oncogene 2001, 20:4497-4506.
81. Heiser A, Coleman D, Dannull J, et al.: Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors. J Clin Invest 2002, 109:409-417.
82. Meidenbauer N, Gooding W, Spitler L, et al.: Recovery of zeta-chain expression and changes in spontaneous IL-10 production after PSA-besed vaccines in patients with prostate cancer. Br J Cancer 2002, 86:168-178. A lucid example of the opportunities offered by immune monitoring. Analysis of ζ chain expression provides evidence for vaccine-mediated improvements in T-cell activation.
83. Eaton JD, Perry MJ, Nicholson S, et al.: Allogeneic whole-cell vaccine: A phase I/II study in men with hormone- refractory prostate cancer. BJU Int 2002, 89:19-26.
84. Sadanaga N, Negashima H, Mashino K, et al.: Dendritic cell vaccination with MAGE peptide is a novel therapeutic approach for gastrointestinal carcinomas. Clin Cancer Res 2001, 7:2277-2284.
85. Miyagi Y, Imai N, Sasatomi T, et al.: Induction of cellular immune responses to tumor cells and peptides in colorectal cancer patients by vaccination with SART3 peptides. Clin Cancer Res 2001, 7:3950-3962.
86. Hawkins WG, Gold JS, Blachere NE, et al.: Xenogeneic DNA immunization in melanoma models for minimal residual disease. J Surg Res 2002, 102:137-143.
87. Musselli C, Ragupathi G, Gilewski T, et al.: Reevaluation of the cellular immune response in breast cancer patients vaccinated with MUC1. Int J Cancer 2002, 97:660-667.
88. Neelapu SS, Baskar S, Kwak LW: Detection of keyhole limpet hemocyanin (KLH)-specific immune responses by intracellular cytokine assay in patients vaccinated with idiotype- KLH vaccine. J Cancer Res Clin Oncol 2001, 127 Suppl 2:R14-R19.
89. Coulie PG, Karanikas V, Colau D, et al.: A monoclonal cytolytic T-lymphocyte response observed in a melanoma patient vaccinated with a tumor-specific antigenic peptide encoded by gene MAGE-3. Proc Natl Acad Sci U S A 2001, 98:10290-10295.
90. Kowalczyk DW, Wlazlo AP, Blaszczyk-Thurin M, et al.: A method that allows easy characterization of tumor-infiltrating lymphocytes. J Immunol Methods 2001, 253:163-175. This publication describes an original method to study immunity, characterizing immunocyte infiltration into matrigel implants mixed with tumor cells.
91. Mathioudakis G, Coder D, Fefer A: Multiparameter cytokine-specific affinity matrix assay for the determination of frequencies and phenotype of antigen-reactive T cells. J Immunol Methods 2002, 260:37-42.